×
About 81,090 results

ALLMedicine™ Anemia Center

Research & Reviews  22,412 results

Safety of linezolid in patients with decreased renal function and trough monitoring: a ...
https://doi.org/10.1186/s40360-022-00628-9
BMC Pharmacology & Toxicology; Liu X, Aoki M et. al.

Dec 2nd, 2022 - Linezolid causes hematological toxicity, mostly thrombocytopenia, which leads to treatment discontinuation and failure. Recent studies revealed that during linezolid therapy, the incidence of treatment-related hematological toxicity is significant...

Successful rescue of renal transplantation with cardiac arrest after electrical storm: ...
https://doi.org/10.1097/MD.0000000000032030
Medicine Li H, Xia Z et. al.

Dec 2nd, 2022 - Most patients with end-stage chronic kidney disease are associated with complications such as renal hypertension, renal anemia, hyperkalemia, water-sodium retention, and disorders of acid-base balance after long-term renal replacement therapy, whi...

Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose ...
https://doi.org/10.1097/MD.0000000000031426
Medicine Miao B, Isachkina AN et. al.

Dec 2nd, 2022 - EPREX®/ERYPO®/PROCRIT® (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as per the recommendation provided by European Medicines Agency. EPIAO® is a biosimil...

The importance of renal function in anemic patients treated with edoxaban after orthope...
https://doi.org/10.1097/MD.0000000000031298
Medicine Izushi Y, Takami Y et. al.

Dec 2nd, 2022 - Edoxaban (Edx) has been approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. However, the risk of anemia with Edx treatment remains elusive. No risk factors for Edx-associated anemia after orthopedic surger...

"Is anemia frequently recognized in gastroschisis compared to omphalocele? A multicente...
https://doi.org/10.1007/s00383-022-05288-8
Pediatric Surgery International; Govani DJ, Trambadia RA et. al.

Dec 2nd, 2022 - "Is anemia frequently recognized in gastroschisis compared to omphalocele? A multicenter retrospective study in southern Japan" by Sugita, K et al.|2022|Govani DJ,Trambadia RA,Chhaniara RA,Mirani ZR,Midha PK,|

see more →

Guidelines  27 results

AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Exp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740554
Gastroenterology Shah SC, Piazuelo MB et. al.

Aug 30th, 2021 - The purpose of this Clinical Practice Update Expert Review is to provide clinicians with guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of the stomach, with a primary focus on atrophic gastritis du...

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improvin...
https://doi.org/10.1016/j.kint.2021.03.020
Kidney International; Babitt JL, Eisenga MF et. al.

Apr 12th, 2021 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis,...

Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.
https://doi.org/10.1053/j.gastro.2020.08.036
Gastroenterology Ko CW, Siddique SM et. al.

Aug 31st, 2020 - Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Altayar O,|blood,diagnosis,etiology,standards,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagn...

GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.
https://doi.org/10.1053/j.gastro.2020.08.043
Gastroenterology

Aug 31st, 2020 - GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.|2020| ,|blood,diagnosis,etiology,standards,methods,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagnosis,pathology,analysis,diag...

AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency ...
https://doi.org/10.1053/j.gastro.2020.06.046
Gastroenterology Ko CW, Siddique SM et. al.

Aug 19th, 2020 - AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Sultan S,|blood,diagnosis,epidemiology,etiology,standards,standards,diagnostic imaging,metabolism,pathology,stan...

see more →

Drugs  1,146 results see all →

Clinicaltrials.gov  2,812 results

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
https://clinicaltrials.gov/ct2/show/NCT03988608

Oct 14th, 2022 - This is a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag will be started at 25 mg/day and increas...

Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis
https://clinicaltrials.gov/ct2/show/NCT04921696

Oct 14th, 2022 - Improving understanding of the role of RBC transfusion and anemia in the development of NEC is important. Several studies characterizing the associations between transfusion, anemia, and NEC were potentially limited by small sample size, study des...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Oct 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Mechanisms Accounting for Unexplained Anemia in the Elderly
https://clinicaltrials.gov/ct2/show/NCT01572506

Oct 14th, 2022 - Anemia occurs commonly and is associated with adverse outcomes in the elderly. In approximately one third of anemia cases in patients over the age of 65 years, the cause of anemia is not readily apparent (unexplained anemia or UA). Of the various ...

Improving White Blood Cell Collection From Healthy Donors
https://clinicaltrials.gov/ct2/show/NCT01553214

Oct 14th, 2022 - Bacterial and fungal infections in neutropenic patients or in patients with inherited disorders of neutrophil function continue to cause substantial morbidity and mortality. In particular, fungal infections are an increasingly important cause of d...

see more →

News  5,756 results

Is Finding and Fixing Iron Deficiency in Heart Failure Beneficial? IRONMAN in Detail
https://www.medscape.com/viewarticle/983652

Nov 30th, 2022 - This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hi. I'm Ileana Piña, heart failure transplant cardiologist and quality chief at Thomas Jefferson in Philadelphia. This is my blog from the American Heart Association meeting in ...

Selpercatinib Approval in RET Fusion+ Solid Tumors Expands Tumor-Agnostic Feasibility
https://www.onclive.com/view/selpercatinib-approval-in-ret-fusion-solid-tumors-expands-tumor-agnostic-feasibility

Nov 23rd, 2022 - Recent FDA approvals for the RET kinase inhibitor selpercatinib (Retivmo) in RET fusion–positive non–small cell lung cancer (NSCLC) and for those with solid tumors bolsters efforts to expand the use of tumor-agnostic drugs in early-stage treatment...

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-induces-strong-response-in-chinese-patients-with-relapsed-refractory-multiple-myeloma

Nov 21st, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) treated at 8 sites in China.1 Investigators said the results from the pivotal phase 2 CARTIFAN...

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma
https://www.onclive.com/view/updated-efficacy-and-safety-of-larotrectinib-in-patients-with-advanced-tropomyosin-receptor-kinase-trk-fusion-positive-thyroid-carcinoma

Nov 18th, 2022 - Background Larotrectinib is a highly selective TRK inhibitor which has shown a 71% overall response rate (ORR) in 28 investigator-evaluable patients with TRK fusion-positive thyroid carcinoma (TC) as of July 2020. We report data on an expanded d...

see more →

Patient Education  283 results see all →